OMNY AF Study Shows Early Gains in AF Ablation
Boston, Massachusetts — February 6, 2026 Johnson & Johnson has presented early clinical outcomes from the OMNY AF Pilot...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Boston, Massachusetts — February 6, 2026 Johnson & Johnson has presented early clinical outcomes from the OMNY AF Pilot...
SAN DIEGO, Feb. 2026 — Field Medical presented new clinical findings from its PULSE clinical study evaluating pulsed field...
IRVINE, Calif., October 10, 2025 — Johnson & Johnson MedTech has announced the launch of the CORE-VA (Catheter-based Outcomes...
